BACKGROUND: Expression profiles of some microRNAs (miRNAs) were associated with clinicopathological findings in human prostate cancer (PC), but the relative expression of miRNAs among Gleason patterns (GPs) remains unclear. In this study, we investigated the expression of several known microRNAs in each GP of PC. METHODS: Formalin-fixed, paraffin embedded (FFPE) tissue samples were obtained from radical prostatectomy (RP) (patient set 1, n = 43, including (GP 3) n = 22, (GP 4) n = 35, and (GP 5) n = 12) and needle biopsy (patient set 2, n = 10, (GP 4) n = 10). Cancer tissues from each GP and adjacent normal counterparts were separately collected using laser-captured microdissection (LCM). Real-time RT-PCR was performed to determine the relative expression of miRNAs, including miR-31-5p, -34c-5p, -96-5p, -182-5p, -183-5p, -205-5p, -221-3p, and -222-3p, which were currently reported to be involved in PC progression. RESULTS: In radical prostatectomy samples, relative expression of miR-31-5p, miR-34c-5p, and miR-205-5p in any GP was significantly decreased compared to normal counterpart. However, no significant difference was detected among GP 3, GP 4, and GP 5. Meanwhile, in the same GP4, expression of miR-31-5p miR-182-5p, and miR-205-5p in cancer tissues obtained from high grade cancer was significantly higher than those obtained from intermediate grade cancer. Validation study using biopsy samples revealed that the relative expression of miR-182-5p was statistically higher in high grade cancer even in same GP4. CONCLUSIONS: We confirmed the expression of miR-182-5p depended on the cancer grade even in same GP 4. Expression of miRNA associated with Gleason grading system may contribute to more accurate preoperative cancer risk evaluation.
BACKGROUND: Expression profiles of some microRNAs (miRNAs) were associated with clinicopathological findings in humanprostate cancer (PC), but the relative expression of miRNAs among Gleason patterns (GPs) remains unclear. In this study, we investigated the expression of several known microRNAs in each GP of PC. METHODS:Formalin-fixed, paraffin embedded (FFPE) tissue samples were obtained from radical prostatectomy (RP) (patient set 1, n = 43, including (GP 3) n = 22, (GP 4) n = 35, and (GP 5) n = 12) and needle biopsy (patient set 2, n = 10, (GP 4) n = 10). Cancer tissues from each GP and adjacent normal counterparts were separately collected using laser-captured microdissection (LCM). Real-time RT-PCR was performed to determine the relative expression of miRNAs, including miR-31-5p, -34c-5p, -96-5p, -182-5p, -183-5p, -205-5p, -221-3p, and -222-3p, which were currently reported to be involved in PC progression. RESULTS: In radical prostatectomy samples, relative expression of miR-31-5p, miR-34c-5p, and miR-205-5p in any GP was significantly decreased compared to normal counterpart. However, no significant difference was detected among GP 3, GP 4, and GP 5. Meanwhile, in the same GP4, expression of miR-31-5p miR-182-5p, and miR-205-5p in cancer tissues obtained from high grade cancer was significantly higher than those obtained from intermediate grade cancer. Validation study using biopsy samples revealed that the relative expression of miR-182-5p was statistically higher in high grade cancer even in same GP4. CONCLUSIONS: We confirmed the expression of miR-182-5p depended on the cancer grade even in same GP 4. Expression of miRNA associated with Gleason grading system may contribute to more accurate preoperative cancer risk evaluation.
Authors: Mohit Sachdeva; Rebecca D Dodd; Zhiqing Huang; Carole Grenier; Yan Ma; Dina C Lev; Diana M Cardona; Susan K Murphy; David G Kirsch Journal: Cancer Lett Date: 2015-08-24 Impact factor: 8.679
Authors: Qinghu Ren; Jiaqian Liang; Jianjun Wei; Olca Basturk; Jinhua Wang; Garrett Daniels; Lan Lin Gellert; Yirong Li; Ying Shen; Iman Osman; Jun Zhao; Jonathan Melamed; Peng Lee Journal: Am J Transl Res Date: 2014-07-18 Impact factor: 4.060
Authors: Mohit Sachdeva; Jeffrey K Mito; Chang-Lung Lee; Minsi Zhang; Zhizhong Li; Rebecca D Dodd; David Cason; Lixia Luo; Yan Ma; David Van Mater; Rebecca Gladdy; Dina C Lev; Diana M Cardona; David G Kirsch Journal: J Clin Invest Date: 2014-09-02 Impact factor: 14.808
Authors: Ratnam S Seelan; Dennis R Warner; Partha M Mukhopadhyay; Sarah A Andres; Irina A Smolenkova; James L Wittliff; M Michele Pisano; Robert M Greene Journal: Anal Biochem Date: 2013-07-30 Impact factor: 3.365
Authors: João Ramalho-Carvalho; Filipa Quintela Vieira; Carmen Jerónimo; Pedro Costa-Pinheiro; Jorge Torres-Ferreira; Jorge Oliveira; Céline S Gonçalves; Bruno M Costa; Rui Henrique Journal: Clin Epigenetics Date: 2015-04-10 Impact factor: 6.551
Authors: Robert K Nam; Yutaka Amemiya; Tania Benatar; Christopher J D Wallis; Jessica Stojcic-Bendavid; Stephanie Bacopulos; Christopher Sherman; Linda Sugar; Magda Naeim; Wenyi Yang; Aiguo Zhang; Laurence H Klotz; Steven A Narod; Arun Seth Journal: J Cancer Date: 2015-09-15 Impact factor: 4.207